Company research
Aquestive Therapeutics, Inc.
CIK 1398733Updated Sep 24, 2026
SecurityAQST · NASDAQ · equity
Name history
MonoSol Rx, Inc. · through Mar 27, 2008
AQST price & chart
Loading TradingView…
NASDAQ:AQST on TradingView ↗About the company
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions, including alopecia areata.
In the news
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences ↗
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky ↗
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
4 filing
144 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
424B3 filing
EFFECT filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 160,425,000Source | 101,424,000Source | 57,418,000Source | 57,070,000Source |
| Property, Plant and Equipment, NetUSD | 3,893,000Source | 3,799,000Source | 4,179,000Source | 4,085,000Source |
| Current assets: | ||||
| Inventory, NetUSD | 6,169,000Source | 6,044,000Source | 6,769,000Source | 5,780,000Source |
| Assets, CurrentUSD | 149,269,000Source | 88,220,000Source | 40,966,000Source | 39,888,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,168,000Source | 3,286,000Source | 1,854,000Source | 2,131,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,621,000Source | 5,182,000Source | 5,557,000Source | 5,211,000Source |
| Other Assets, NoncurrentUSD | 2,642,000Source | 4,223,000Source | 5,438,000Source | 6,451,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 194,087,000Source | 161,580,000Source | 163,905,000Source | 175,624,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 122,000Source | 91,000Source | 69,000Source | 55,000Source |
| Additional Paid in CapitalUSD | 413,214,000Source | 302,967,000Source | 212,521,000Source | 192,598,000Source |
| Retained Earnings (Accumulated Deficit)USD | -446,998,000Source | -363,214,000Source | -319,077,000Source | -311,207,000Source |
| Stockholders' Equity Attributable to ParentUSD | -33,662,000Source | -60,156,000Source | -106,487,000Source | -118,554,000Source |
| Liabilities and EquityUSD | 160,425,000Source | 101,424,000Source | 57,418,000Source | 57,070,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 47,608,000Source | 18,865,000Source | 18,308,000Source | 39,528,000Source |
| Operating Lease, Liability, CurrentUSD | 631,000Source | 510,000Source | 390,000Source | 255,000Source |
| Accounts Payable, CurrentUSD | 29,862,000Source | 10,287,000Source | 8,926,000Source | 9,946,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,337,000Source | 4,968,000Source | 5,399,000Source | 5,085,000Source |
| Other Liabilities, NoncurrentUSD | 7,269,000Source | 2,395,000Source | 2,016,000Source | 2,034,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,029,000Source | 5,907,000Source | 6,497,000Source | 7,967,000Source |
| Long-term DebtUSD | 45,000,000Source | 45,000,000Source | 45,000,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,624,000Source | 7,099,000Source | 2,689,000Source | 4,381,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 126,000Source | -725,000Source | 989,000Source | 1,743,000Source |
| Increase (Decrease) in Accounts PayableUSD | 19,523,000Source | 2,782,000Source | -1,020,000Source | 1,633,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -52,432,000Source | -35,759,000Source | -6,380,000Source | -9,789,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -562,000Source | -159,000Source | -995,000Source | -2,524,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 562,000Source | 159,000Source | 995,000Source | 1,024,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 810,000Source | 1,101,000Source | 11,000Source | 3,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 102,617,000Source | 83,592,000Source | 3,974,000Source | 11,562,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 49,623,000Source | 47,674,000Source | -3,401,000Source | -751,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 121,169,000Source | 71,546,000Source | 23,872,000Source | 27,273,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,098,000Source | 7,097,000Source | 4,602,000Source | 6,436,000Source |
| Income Taxes Paid, NetUSD | 0Source | 305,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,624,000Source | 7,099,000Source | 2,689,000Source | 4,381,000Source |
| Amortization of Debt Issuance CostsUSD | 243,000Source | 236,000Source | 220,000Source | 208,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 10,995,000Source | 10,714,000Source | 1,972,000Source | 215,000Source |
| Amortization of Intangible AssetsUSD | 0Source | 78,000Source | 157,000Source | 116,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | 26,000Source | 23,000Source | 27,000Source | 167,000Source |
| DepreciationUSD | 548,000Source | 640,000Source | 1,153,000Source | 2,270,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | -1,382,000Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | -14,000Source | 245,000Source | 0Source |
| InterestExpenseNonoperatingUSD | 11,120,000Source | 11,122,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -83,784,000Source | -44,137,000Source | -7,870,000Source | -54,410,000Source |
| Operating ExpensesUSD | — | — | — | 89,746,000Source |
| Payments of Financing CostsUSD | — | 0Source | 4,643,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 1,270,000Source | 732,000Source | 1,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 44,545,000Source | 57,561,000Source | 50,583,000Source | 47,680,000Source |
| Cost of RevenueUSD | 18,555,000Source | 17,872,000Source | 20,831,000Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 79,849,000Source | 50,180,000Source | 31,750,000Source | 52,879,000Source |
| Operating Income (Loss)USD | -71,051,000Source | -30,771,000Source | -15,102,000Source | -42,066,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -83,784,000Source | -44,151,000Source | -7,625,000Source | -54,410,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -14,000Source | 245,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -83,784,000Source | -44,137,000Source | -7,870,000Source | -54,410,000Source |
| Earnings Per Share, BasicUSD per share | -0.78Source | -0.51Source | -0.13Source | -1.12Source |
| Earnings Per Share, DilutedUSD per share | -0.78Source | -0.51Source | -0.13Source | -1.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 106,926,528Source | 86,726,211Source | 61,255,864Source | 48,734,377Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 106,926,528Source | 86,726,211Source | 61,255,864Source | 48,734,377Source |
| Interest Expense (non-operating)USD | 11,120,000Source | 11,122,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 0Source | 78,000Source | 157,000Source | 116,000Source |
| Costs and ExpensesUSD | 115,596,000Source | 88,332,000Source | 65,685,000Source | — |
| Current Income Tax Expense (Benefit)USD | 0Source | -14,000Source | 245,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 548,000Source | 718,000Source | 1,345,000Source | 2,387,000Source |
| Interest and Other IncomeUSD | — | — | — | 99,000Source |
| Interest ExpenseUSD | — | — | 6,337,000Source | 6,552,000Source |
| Operating ExpensesUSD | — | — | — | 89,746,000Source |
| Research and Development ExpenseUSD | 17,192,000Source | 20,280,000Source | 13,104,000Source | 17,481,000Source |
Filing attachments
ef20053945_ex99-1.htm · 8-K · 2025-08-15
EX-99.1 4 ef20053945_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Project Academy Corporate Presentation Strictly Confidential. Do Not Distribute. Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,”…
Read attachment ↗ef20053945_ex99-2.htm · 8-K · 2025-08-15
EX-99.2 5 ef20053945_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., August 14, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its …
Read attachment ↗ef20053941_ex99-1.htm · 8-K · 2025-08-14
EX-99.1 2 ef20053941_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of Anaphylm for the emergency treatment of allergic…
Read attachment ↗